Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 19/20 | 0.79 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.62 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.62 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14340828 | 0.90 | HCAR2 (0.77) | HCAR2 | |
| SCHEMBL12671515 | 0.89 | HCAR2 (0.89) | HCAR2CYP2C8CYP2C9 | |
| SCHEMBL31060511 | 0.89 | HCAR2 (0.89) | HCAR2CYP2C8CYP2C9 | |
| SCHEMBL14340790 | 0.88 | HCAR2 (1.00) | HCAR2CYP2C8CYP2C9 | |
| SCHEMBL14340799 | 0.86 | HCAR2 (1.00) | HCAR2CYP2C8CYP2C9 | |
| SCHEMBL14340814 | 0.86 | HCAR2 (1.00) | HCAR2CYP2C8CYP2C9 | |
| SCHEMBL2275482 | 0.84 | HCAR2 (0.71) | HCAR2 | |
| SCHEMBL14340819 | 0.84 | HCAR2 (1.00) | HCAR2CYP2C8CYP2C9 | |
| SCHEMBL10497116 | 0.83 | HCAR2 (0.78) | HCAR2CYP2C8CYP2C9 | |
| SCHEMBL14340798 | 0.83 | HCAR2 (0.75) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281969-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | GPR119, FFAR1, HCAR1 | HCAR2 7/4885AKR1C3 87/4885AKR1C2 90/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.